The Comprehensive Genetic Test for Marfan Syndrome utilizes next-generation sequencing (NGS) to examine 36 genes associated with Marfan syndrome and connective tissue disorders. It is a targeted gene panel specifically designed to support accurate diagnosis, risk assessment, and prevention.
More Information
The Comprehensive Genetic Test for Marfan Syndrome is a targeted genetic test designed to evaluate hereditary causes of Marfan syndrome and related connective tissue disorders. The comprehensive genetic test for Marfan syndrome includes the analysis of a set of genes, along with selected non-coding variants, enabling a comprehensive assessment of genetic factors associated with these conditions. It is primarily used in individuals with clinical features suggestive of Marfan syndrome or overlapping connective tissue disorders. These conditions are characterized by abnormalities in connective tissue integrity, affecting multiple organ systems, particularly the cardiovascular, ocular, and skeletal systems.
The comprehensive genetic test for Marfan syndrome includes key genes such as FBN1, TGFBR1, TGFBR2, and SMAD3, which are involved in extracellular matrix structure and transforming growth factor-beta (TGF-β) signaling pathways. FBN1 encodes fibrillin-1, a critical component of connective tissue microfibrils that provide structural support and regulate growth factor signaling. TGF-β pathway genes play a central role in cellular growth, differentiation, and tissue homeostasis. Disruptions in these pathways lead to impaired connective tissue integrity and abnormal tissue remodeling. The comprehensive genetic test for Marfan syndrome is indicated in individuals with features suggestive of Marfan syndrome or related connective tissue disorders affecting the aorta, eyes, or skeleton.
The clinical spectrum of Marfan syndrome is broad and highly variable, ranging from mild skeletal features to life-threatening cardiovascular complications. Common manifestations include tall stature, arachnodactyly, scoliosis, chest wall deformities, and ocular abnormalities such as ectopia lentis. Cardiovascular involvement is a major concern and includes aortic aneurysm, aortic dissection, and mitral valve regurgitation. Clinical features may develop progressively and can appear from infancy to adulthood. Significant phenotypic overlap exists with other connective tissue disorders, contributing to diagnostic complexity and variability even among affected individuals within the same family.
The purpose of the comprehensive genetic test for Marfan syndrome is to identify pathogenic variants associated with Marfan syndrome and related disorders, supporting accurate diagnosis and differentiation from clinically overlapping conditions. Genetic findings contribute to improved understanding of the molecular basis of connective tissue disorders and support appropriate disease classification. The identification of specific genetic alterations assists in risk assessment, prognosis evaluation, and the development of individualized long-term monitoring strategies.
A higher genetic risk is confirmed when pathogenic mutations are found in genes associated with Marfan syndrome, including FBN1, TGFBR1, and TGFBR2. A lower risk may be inferred when no mutations are detected, though comprehensive clinical follow-up is still essential. The integration of genetic data with clinical findings and imaging evaluation is critical for precise diagnosis, prognosis, and long-term patient care.
The test is performed in a clinical laboratory accredited to ISO 15189 and certified by CLIA and CAP, ensuring the validity, accuracy and international recognition of the results.
